Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14095965 | 0.91 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2CYP1A2GAA | |
| SCHEMBL14137019 | 0.89 | CYP1A2 (0.65) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14095985 | 0.89 | KMT2A (0.64) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14095976 | 0.88 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2CYP1A2GAA | |
| SCHEMBL13956729 | 0.86 | MAPT (0.60) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4362279 | 0.85 | MAPT (0.70) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4361509 | 0.85 | HPGD (0.75) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13956723 | 0.84 | ALDH1A1 (0.67) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14095962 | 0.84 | RNASEL (0.67) | ALDH1A1MAPTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2864417 | 0.83 | NPC1 (0.63) | ALDH1A1MAPTSMN1; SMN2KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207760-A1 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv | RNASE1, SARS1, EIF2AK2 | ALDH1A1 2930/4885MAPT 4038/4885SMN1; SMN2 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.